Demystifying Alpha-1 Antitrypsin (A1AT) Deficiency and Chronic Obstructive Pulmonary Disease (COPD): A Practical Guidance for Clinicians
WebcastFaculty
OVERVIEW
Demystifying Alpha-1 Antitrypsin (A1AT) Deficiency and Chronic Obstructive Pulmonary Disease (COPD): A Practical Guidance for Clinicians is organized by National Association for Continuing Education (NACE) and will be held during Aug 18, 2017 - Aug 17, 2018.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Description:
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is progressive and associated with an enhanced chronic inflammatory response in the lung to noxious particles or gases.
Deficiency of alpha-1 antitrypsin (AAT) is the best-studied genetic risk factor for COPD and one of the most common genetic disorders among Caucasians. The availability of specific therapy for AATD makes it possible to improve outcomes, but however, AATD is underrecognized and undertreated. This program will discuss diagnosis and treatment options for patients with COPD and AATD, with the most recent recommendations from the GOLD 2017 report.
Conference Objectives are:
• Discuss the pathophysiology of Alpha-1 Antitrypsin Deficiency (AATD).
• Utilize appropriate screening for AATD.
• Incorporate AATD testing into routine chronic obstructive pulmonary disease (COPD) management algorithm.
• Discuss treatment options for AATD and latest GOLD guideline recommendations.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Description:
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is progressive and associated with an enhanced chronic inflammatory response in the lung to noxious particles or gases.
Deficiency of alpha-1 antitrypsin (AAT) is the best-studied genetic risk factor for COPD and one of the most common genetic disorders among Caucasians. The availability of specific therapy for AATD makes it possible to improve outcomes, but however, AATD is underrecognized and undertreated. This program will discuss diagnosis and treatment options for patients with COPD and AATD, with the most recent recommendations from the GOLD 2017 report.
Conference Objectives are:
• Discuss the pathophysiology of Alpha-1 Antitrypsin Deficiency (AATD).
• Utilize appropriate screening for AATD.
• Incorporate AATD testing into routine chronic obstructive pulmonary disease (COPD) management algorithm.
• Discuss treatment options for AATD and latest GOLD guideline recommendations.
Additional details will be posted as soon as they are available.
SPECIALITIES
Pulmonary MedicinePrimary Care
Quick Links